Gaps in patients' access to hematology care in Central and Eastern European EU member states
The main goal of this study was to identify and assess the differences in patient access in Central Eastern European (CEE) cancer care (with a focus on chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) in eight individual CEE countries. Although patient access has been captured and operationalized via several indicators, the concept of patient access is often restricted to length of the reimbursement process and delays in treatment decisions.
Therefore, a comprehensive, multiple-criteria decision analysis framework that reflects the entire care delivery pathway in CLL and MM was developed and analyzed. Please have a look at this short video that explains concept and methodology.
Kindly please find key study results, analyzed across 4 key dimensions (Up-to-date clinical guidelines, Access to reimbursement/public funding, Access to local real-world evidence data and Role of patient advocacy groups) in Executive Summary.